A New Paper Shifts the Blame for Aging Spots to Skin's Surface Cells

A paper published May 7, 2026, in the Journal of Investigative Dermatology lays out a case for rethinking what causes the dark spots that accumulate on aging, sun-exposed skin. The team, led by Mattheus Xing Rong Foo and Oliver Dreesen, took paired biopsies from nine Korean donors with Fitzpatrick skin type III or IV, sampling both a lentigo lesion and the normal-looking skin next to it on each person's face. That paired design lets the researchers compare spot and non-spot tissue from the same person, which controls for a lot of the variation that would otherwise come from comparing different people's skin.

The strength of the paper is in what kind of evidence it stacks on top of the biopsies. Staining for lamin B1 and p16INK4A, markers used to flag senescent cells, showed these markers concentrated in epidermal keratinocytes inside lentigo lesions, not just in the dermal fibroblasts underneath. Ki-67 staining measured how much those cells had stopped dividing, and TRP1 marked the melanocytes actually producing pigment. None of that, on its own, proves the senescent keratinocytes are driving the pigmentation rather than simply sitting near it. The authors close that gap with a melanocyte-keratinocyte co-culture experiment, in which senescent keratinocytes actively stimulate pigment production, transport, and accumulation in melanocytes grown alongside them. That is a functional test, not a correlation lifted from fixed tissue, and it is the detail that moves this past a staining survey into a mechanistic claim.

The finding pushes against a model that has dominated the field since a 2018 paper in Theranostics argued that senescent dermal fibroblasts drive lentigo pigmentation by losing SDF1 secretion, which paradoxically raises melanin production in nearby melanocytes through MITF and tyrosinase. The new JID paper does not disprove that fibroblast pathway. It adds keratinocytes as a second, independently acting source of the same downstream effect. A separate 2026 paper in the International Journal of Molecular Sciences, using doxorubicin-induced senescent keratinocytes in vitro, reaches a similar keratinocyte-centric conclusion and identifies IGFBP3 and NGF as the specific secreted factors behind a 33% and 17% increase in melanocyte activity, respectively. Two groups landing on the same shift within months of each other, through different methods, is itself a data point worth weighing alongside either paper's individual results.

What the JID paper cannot do is settle how far its mechanism travels beyond the room where it was tested. Nine donors is a small cohort even by the standards of biopsy-based dermatology studies, and all nine were Korean with Fitzpatrick III or IV skin, the population in which senile lentigo is flagged as a particularly visible cosmetic concern. The 2018 fibroblast study it responds to drew on a largely different population profile, so a reader cannot yet tell whether keratinocyte senescence is a universal driver of lentigo or a pathway more pronounced in the skin types this paper sampled. The study also stops at mechanism. It does not test whether clearing senescent keratinocytes changes a lesion, and the clinical tools currently used on lentigo, Q-switched lasers, hydroquinone, tretinoin, were designed to fade existing pigment rather than touch the senescent cell population the paper implicates.

What stays with you from the paper is the co-culture dish itself: keratinocytes that have stopped dividing, sitting next to melanocytes that have not, and pigment moving between them anyway.